Showing results (81-90 of 671) with videos related to
Sort By:
Pageof 68
F1000Research|August 24, 2019
Turning the tables: A university league-table based on quality not quantityAdrian G Barnett, David MoherPublic Health Reports (Washington, D.C. : 1974)|March 20, 2010
Characteristics of Asian and Pacific Islanders admitted to U.S. drug treatment programs in 2005Wynnie Wong, Paul G BarnettJournal of Neuroscience Methods|September 1, 1988
Basic instrumentation for fast cyclic voltammetryJ Millar, T G BarnettClinical Pharmacology and Therapeutics|May 1, 1982
Phencyclidine and phenylcyclohexene disposition after smoking phencyclidineC E Cook, D R Brine, G D Quin, et al.The Journal of Pharmacology and Experimental Therapeutics|June 1, 1994
Anti-phencyclidine monoclonal Fab fragments markedly alter phencyclidine pharmacokinetics in ratsJ L Valentine, L W Arnold, S M OwensDrug Metabolism and Disposition: the Biological Fate of Chemicals|February 1, 1995
Antipeptide antibodies targeted against specific regions of rat CYP2D1 and human CYP2D6E M Laurenzana, S L Sorrels, S M OwensNIDA Research Monograph|January 1, 1982
Radioimmunoanalysis of delta-9-THC in blood by means of an 125I tracerS M Owens, A J McBay, H M ReisnerDrug Metabolism and Disposition: the Biological Fate of Chemicals|June 20, 2000
The effect of rate of drug administration on the extent and time course of phencyclidine distribution in rat brain, testis, and serumJ W Proksch, W B Gentry, S M OwensThe Journal of Pharmacology and Experimental Therapeutics|April 1, 1996
Phencyclidine metabolite irreversible binding in the rat: gonadal steroid regulation and CYP2C11S R Shelnutt, T M Badger, S M OwensClinical Pharmacology and Therapeutics|July 30, 2010
Anti-(+)-methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addictionW B Gentry, D Rüedi-Bettschen, S M OwensPageof 68